Louise Chen
Stock Analyst at Scotiabank
(3.14)
# 1,154
Out of 4,955 analysts
299
Total ratings
45.8%
Success rate
0.57%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $19.48 | +310.68% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.79 | +404.20% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.57 | -3.91% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.79 | +572.27% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.99 | +175.14% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $48.76 | +12.80% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.47 | +332.28% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $51.34 | -2.61% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.99 | +150.63% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $11.90 | +42.86% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $43.72 | +60.11% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $11.95 | +318.41% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $14.75 | +103.39% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $34.24 | +60.63% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.86 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $55.60 | +187.77% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.63 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.77 | +74.62% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $179.47 | +19.80% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.93 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $86.92 | +78.32% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.67 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $712.73 | +24.17% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.48 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.69 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.08 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.10 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $68.80 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $211.97 | -5.65% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.74 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.66 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.75 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.17 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $602.09 | +53.63% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.81 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.66 | +1,678.39% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.83 | +173.72% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $4.74 | +427.43% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.08 | +210.95% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.75 | +217.46% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.10 | +354.55% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.33 | +2,653.14% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.86 | +90,633,124.13% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $378.81 | -31.89% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $18.21 | -17.61% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.33 | +3,673.58% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.39 | +1,344.04% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.04 | +539.20% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $19.48
Upside: +310.68%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.79
Upside: +404.20%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.57
Upside: -3.91%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.79
Upside: +572.27%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.99
Upside: +175.14%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $48.76
Upside: +12.80%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.47
Upside: +332.28%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $51.34
Upside: -2.61%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.99
Upside: +150.63%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $11.90
Upside: +42.86%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $43.72
Upside: +60.11%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $11.95
Upside: +318.41%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $14.75
Upside: +103.39%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $34.24
Upside: +60.63%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.86
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $55.60
Upside: +187.77%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.63
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.77
Upside: +74.62%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $179.47
Upside: +19.80%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.93
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $86.92
Upside: +78.32%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.67
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $712.73
Upside: +24.17%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.48
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.69
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.08
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.10
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $68.80
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $211.97
Upside: -5.65%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.74
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.66
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.75
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.17
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $602.09
Upside: +53.63%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.81
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.66
Upside: +1,678.39%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.83
Upside: +173.72%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $4.74
Upside: +427.43%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.08
Upside: +210.95%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.75
Upside: +217.46%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.10
Upside: +354.55%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.33
Upside: +2,653.14%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.86
Upside: +90,633,124.13%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $378.81
Upside: -31.89%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $18.21
Upside: -17.61%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.33
Upside: +3,673.58%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.39
Upside: +1,344.04%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.04
Upside: +539.20%